LARP1 silencing inhibited cell migration in prostate cancer [58] and cell proliferation in colorectal cancer [59], and sensitized ovarian cancer cells to cisplatin, paclitaxel and gemcitabine [60]. This evidence concerns the gene LARP1 and colorectal cancer.